Outcomes Insights Team

Mark DanesePresident
Mark Danese, MHS, PhD, has over 20 years of experience in epidemiology and outcomes research. He received his masters degree in Biostatistics in 1997, and his doctorate in Epidemiology in 1999, both from The Johns Hopkins University. While completing his degrees, Dr. Danese received funding from the National Eye Institute to study the design and conduct of clinical trials, and was a member of the Johns Hopkins Center for Clinical Trials. His doctoral research focused on the value of testing for thyroid disease, including a cost-effectiveness model and an analysis of the Cardiovascular Health Study thyroid data. Beginning in 2000, he worked for Amgen, Inc., in both the Global Health Economics and Global Epidemiology departments. In December 2003, founded Outcomes Insights, Inc.

Dr. Danese’s expertise is in the design and analysis of studies using observational data, creation of budget impact and cost-effectiveness models, and the design of population-based simulation models. He has over 50 peer-reviewed manuscripts published in journals including JAMA, Blood, Journal of Bone and Mineral Research, Cancer, American Journal of Kidney Diseases, Value in Health, and the Journal of Clinical Endocrinology and Metabolism.

Dr. Danese is a collaborator with the Observational Health Data Science and Informatics (OHDSI) collaborative, helping to develop open-source tools to improve the conduct of observational studies. He is also a member of the following organizations: the American Statistical Association, Academy Health, the Society for Medical Decision Making, the International Society for Pharmacoepidemiology, the American Medical Informatics Association, and the International Society for Pharmacoeconomics and Outcomes Research.

direct line: +1.805.498.0034

Quan DoanVice President
Quan Doan, MSHS, PharmD, has 8 years of experience in outcomes research consulting. His primary area of interest is the application of research design to inform drug policy decision making. This includes the appraisal of evidence, modeling of health care data, and evaluation of costs and outcomes. He received his Doctor of Pharmacy degree in 1998 at the University of Maryland at Baltimore. In the following year, he completed a residency program at Health Core and the Philadelphia College of Pharmacy which focused on health outcomes research and ambulatory care pharmacy practice. In addition, he received his training in health services research at UCLA’s School of Public Health.

Prior to joining Outcomes Insights, Inc., Dr. Doan worked for 5 years at Cerner LifeSciences (formerly Zynx Health). In this capacity, he worked on a wide variety of projects supporting product development for clients in major pharmaceutical and biotech companies including evidence synthesis (e.g., literature review, meta-analysis), economic evaluation (e.g., cost-effectiveness analysis, cost-utility analysis, cost-of-illness and budget impact estimation), value assessment (e.g., global value dossier, AMCP dossier) and secondary database research. Prior to this, Dr. Doan spent 2 years at Health Process Management conducting cost-effectiveness evaluation alongside clinical trials.

direct line: +1.805.367.7485

Deborah LubeckVice President
Deborah Lubeck, Ph.D. has twenty-five years of experience in health economics and outcomes research. She has authored or coauthored over one hundred sixty peer-reviewed publications, and prepared a similar number of scientific meeting presentations. Deborah’s research focuses on the design and analysis of longitudinal observational studies, including analytic methods, the inclusion of longitudinal patient reported data on healthcare resource utilization, burden of illness, and quality of life. During her academic tenure at Stanford University and the University of California, San Francisco, Dr. Lubeck was involved in the design and implementation of national and multinational observational studies in rheumatology, HIV, oncology, and community studies of aging populations.

Dr. Lubeck also has been involved in research studies examining the efficacy and cost-utility of therapies for rheumatoid arthritis, osteoarthritis, HIV-infection, gastrointestinal conditions, cardiovascular disease, chronic kidney disease, multiple solid tumors, and hematologic malignancies. In addition, Deborah has been involved in the design and validation of several patient-reported quality of life instruments, including instruments for rheumatoid arthritis, osteoarthritis, HIV-infection, prostate cancer, and patient satisfaction with care.

Dr. Lubeck worked in Health Economics and Outcomes Research Departments at Amgen, Inc. and Genentech, Inc. and was Vice President, Health Economics and Outcomes Research at ICON and PAREXEL. Prior to her work in industry she was on the faculty of the Department of Urology at the University of California, San Francisco and the Department of Immunology, Division of Rheumatology, Stanford University. She has a BA from Northwestern University and a Ph.D. in Economics from the University of California, Berkeley. She currently serves on the Editorial Board of Drugs in Context and is a peer-reviewer for multiple clinical and health services research journals.

direct line: +1.805.367.7484

Michelle GleesonResearch Director
Michelle Gleeson, PhD, specializes in statistical analysis and data manipulation. She received her Doctorate in Sociology in 2002 from Duke University. Dr. Gleeson was extensively trained in statistical analysis and she has leveraged those skills in a number of subject areas over the course of her career including education, social welfare policy, drug abuse research, health insurance practices and health services research.

For the past 14 years, Dr. Gleeson has worked in health services research. As a consultant, she focuses on preparing, managing and analyzing data using a number of software packages (R, SAS, Stata). Areas of analysis she publishes in are utilization and cost, prevalence of disease, course and extent of disease and methodology. Therapeutic areas that she has concentrated on include: oncology (lymphoma, breast, ovarian, prostate, lung), diabetes, rheumatoid arthritis, immune thrombocytopenic purpura, chronic kidney disease and end stage kidney disease.

Dr. Gleeson specializes in conducting multivariate quantitative analysis and secondary analysis on longitudinal and cross sectional data and has extensive experience with a wide assortment of data sources such as Medicare, SEER, USRDS, CPRD, NHANES, NIS, Marketscan, Humedica, MedAssets, and Health Facts.

direct line: +1.805.367.7491

Marc HalperinResearch Scientist
Marc Halperin holds a BA in Physics from the University of California, Santa Barbara and a Certificate in Applied Biostatistics from the University of Washington. As a part of his Physics degree, Mr. Halperin gained valuable experience in problem solving and computer programming.

Mr. Halperin’s programming expertise includes C++, Java, and Visual Basic in addition to web based languages such as PHP and JavaScript. He has significant experience in statistical programming in both SAS, earned SAS Certified Base Programmer for SAS 9 certificate in 2014, and R. Since joining Outcomes Insights in 2009, he has gained experience building cost effectiveness models in the decision tree software TreeAge® as well as building Excel® based budget impact models and cost effectiveness models. He also currently maintains the Outcomes Insights website in addition to all other ongoing web-based projects.

direct line: +1.805.367.7483

Jennifer DuryeaResearch Scientist
Jennifer Duryea, MPH, holds a Bachelor of Science in Psychobiology and a Master of Public Health in Healthcare Management and Policy from the University of California, Los Angeles. Prior to Outcomes Insights, Ms. Duryea spent nearly a decade working her way up through the ranks of Medical Applications Corporation and came to oversee the Technical Support and Billing Service departments, obtaining extensive experience in medical billing and health information technology. Responsibilities include developing medical claims and billing software for over 200 medical practices in various specialties in Southern California, Nevada and Guam; training and managing clinicians and administrators on billing software; creating and managing a medical billing service department; and creating, sending and following up on medical claims for various payers and provider specialties. Her tenure at Medical Applications Corporation gave her first-hand experience with clinicians; payer policies, trends, and reimbursement; and the use of Health Information Technology in private practices.

Ms. Duryea’s current projects at Outcomes Insights include building economic models, data analysis, and medical data research, including medical coding and analyzing payer policies. Ms. Duryea is also a frequent contributor to the OHDSI community, where she has helped develop ETL documents for various datasets and provided expertise on OHDSI’s vocabulary development.

direct line: +1.805.367.7481

Ryan DuryeaLead Software Developer
Ryan Duryea holds a BS in Computer Science from Texas Christian University. He has nearly a decade of experience in Health IT industry developing clinical healthcare software. He is experienced with a wide range of programming languages such as C, JavaScript, and Perl but is most passionate about Ruby. He has a strong background in Linux and Open Source technologies and has contributed to well over a dozen Open Source projects. Mr. Duryea serves as the Project Lead on most software development efforts.

In recent years, he created an open-source language (ConceptQL) that unambiguously defines and structures a set of criteria in a flexible, easily parse-able, and human readable, format to serve as a foundation for the Jigsaw suite of tools. He is also a regular contributor to several projects in the OHDSI community

direct line: +1.805.367.7486

Reina WeinstockResearch Analyst
Sherry DaneseVice President
Sherry has over 20 years of strategic and marketing consulting in the pharmaceutical and healthcare industry. She brings broad functional expertise, including strategic planning, product and franchise optimization, pipeline and in-line marketing, market research, forecasting, sales, sales operations, and regulatory affairs. This diverse skill set dovetails well with the recent culture of open innovation in healthcare, with engagements focusing on growth strategies for products, portfolios, and adjacencies; innovation in personalized medicine, diagnostics, health information technology, and hospital solutions; and commercial landscape and opportunity assessments in emerging ecosystems.

Previously, Sherry was a Director of Marketing at Amgen, with responsibility for a U.S. and global nephrology product launch, a Vice President at Migliara/Kaplan Associates (now Kantar Health), and a Regulatory Review Officer at the FDA with responsibility for drug labeling and other branding materials for neuropharmacology, oncology, respiratory, and anti-infectives drug products. She began her career as a sales & marketing representative for Eli Lilly and Company. Over this time, she has cultivated experience in a broad array of therapeutic areas including neurology, psychiatry gastroenterology, oncology, anti-infectives, respiratory, women’s health, and nephrology. Sherry earned a M.B.A. from the University of Virginia’s Darden School of Business and a B.S. in Chemistry from the University of Virginia.


Daryl Twitchell
Daryl has over 20 years of experience in strategic consulting, business innovation, product development, venture investing and M&A. He brings a multi-disciplinary approach to evaluating business opportunities, deploying investment resources and capitalizing on emerging market trends and dislocations to build profitable enterprises. Daryl has helped pharma, medical device, health services and med tech companies develop growth strategies, identify expansion opportunities, and transform their business models. He has also worked with clients in financial services, technology, digital media, consumer products, and retail, and has advised investment teams and venture funds that are driving innovation in healthcare.

Previously, Daryl was a Senior Vice President at Lehman Brothers responsible for strategic investments, a Director and Global Head of Marketing at Citigroup where he managed product development, marketing and sales force activities, and a Director of Strategic Planning and Business Development at American Express, responsible for the development of new businesses and strategic investments. He began his career as a management consultant with Corporate Decisions, Inc. (now Oliver Wyman), focused on customer-driven growth strategies. Daryl has a B.A. from Brown University (Phi Beta Kappa, Magna Cum Laude) and an M.B.A. from Yale University.